UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 55

Sortiert nach

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

The Lancet (British edition), 2010-06, Vol.375 (9733), p.2234-2243

2010

Volltextzugriff (PDF)

Growth Hormone plus Childhood Low-Dose Estrogen in Turner's Syndrome

The New England journal of medicine, 2011-03, Vol.364 (13), p.1230-1242

2011

Volltextzugriff (PDF)

Identifying solutions to psychological insulin resistance: An international study

Journal of diabetes and its complications, 2019-04, Vol.33 (4), p.307-314

2019

Volltextzugriff (PDF)

Growth Hormone Is Effective in Treatment of Short Stature Associated with Short Stature Homeobox-Containing Gene Deficiency: Two-Year Results of a Randomized, Controlled, Multicenter Trial

The journal of clinical endocrinology and metabolism, 2007-01, Vol.92 (1), p.219-228

2007

Volltextzugriff (PDF)

Key factors for overcoming psychological insulin resistance: an examination of patient perspectives through content analysis

BMJ open diabetes research & care, 2019-12, Vol.7 (1), p.e000723

2019

Volltextzugriff (PDF)

Characterization of People Achieving Different Weight Reduction Categories with Tirzepatide

Obesity (Silver Spring, Md.), 2023-11, Vol.31, p.284-285

2023

Volltextzugriff (PDF)

Predictors of Achieving Weight Reduction ≥30% with Tirzepatide in People with Obesity in SURMOUNT-1

Obesity (Silver Spring, Md.), 2023-11, Vol.31, p.285-285

2023

Volltextzugriff (PDF)

Weight Reduction is Associated with Improved Quality of Life in Patients with Obesity: SURMOUNT-1

Obesity (Silver Spring, Md.), 2023-11, Vol.31, p.183-183

2023

Volltextzugriff (PDF)

Characteristics and Efficacy of Tirzepatide in Participants with Young-Onset Obesity in SURMOUNT-1

Obesity (Silver Spring, Md.), 2023-11, Vol.31, p.248-248

2023

Volltextzugriff (PDF)

Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis

Diabetes therapy, 2015-09, Vol.6 (3), p.317-328

2015

Volltextzugriff (PDF)

Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26‐week PRONTO‐T1D study

Diabetes, obesity & metabolism, 2020-10, Vol.22 (10), p.1799-1807

2020

Volltextzugriff (PDF)

1702836 Tirzepatide Improved Health-Related Quality of Life in Adults with Obesity or Overweight: Results from the SURMOUNT-3 phase 3 trial

Endocrine practice, 2024-05, Vol.30 (5), p.S69-S69

2024

Volltextzugriff (PDF)

1704957 Tirzepatide Improves Health-Related Quality of Life in Participants With Obesity or Overweight and Type 2 Diabetes: Results From Phase 3 SURMOUNT-2 Trial

Endocrine practice, 2024-05, Vol.30 (5), p.S70-S70

2024

Volltextzugriff (PDF)

1696673 Weight reduction over time in tirzepatide-treated participants by early weight loss response – post hoc analysis in SURMOUNT-1

Endocrine practice, 2024-05, Vol.30 (5), p.S66-S66

2024

Volltextzugriff (PDF)

Tolerability and Weight Reduction of Tirzepatide in Adults With Obesity or Overweight

Obesity (Silver Spring, Md.), 2023-11, Vol.31, p.31-31

2023

Volltextzugriff (PDF)

Baseline Characteristics Associated with Time to Weight Plateau with Tirzepatide in SURMOUNT-1

Obesity (Silver Spring, Md.), 2023-11, Vol.31, p.177-177

2023

Volltextzugriff (PDF)

1704946 Improvements in Physical Functioning Among Participants With Obesity With Limitations in Physical Function at Baseline: Results from SURMOUNT-1 and SURMOUNT-2 Trials

Endocrine practice, 2024-05, Vol.30 (5), p.S70-S70

2024

Volltextzugriff (PDF)

1089-P: Ultra Rapid Lispro (URLi) Improves Postprandial Glucose (PPG) Control and Time in Range (TIR) in T1D Compared with Humalog (Lispro): PRONTO-T1D Continuous Glucose Monitoring (CGM) Substudy

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

Phase 2, randomized, open‐label study of ramucirumab in combination with first‐line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non–small cell lung cancer

Cancer, 2015-03, Vol.121 (6), p.883-892

2015

Volltextzugriff (PDF)

Correlates of basal insulin persistence among insulin-naïve people with type 2 diabetes: results from a multinational survey

Current medical research and opinion, 2017-10, Vol.33 (10), p.1843-1851

2017

Volltextzugriff (PDF)

1112-P: Ultra Rapid Lispro (URLi) Lowers Postprandial Glucose (PPG) and More Closely Matches Normal Physiological Glucose Response Compared with Other Rapid Insulin Analogs

Diabetes (New York, N.Y.), 2019-06, Vol.68

2019

Volltextzugriff (PDF)

1112-P: Ultra Rapid Lispro (URLi) Lowers Postprandial Glucose (PPG) and More Closely Matches Normal Physiological Glucose Response Compared with Other Rapid Insulin Analogs

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

144-OR: Ultra Rapid Lispro (URLi) Improves Postprandial Glucose (PPG) Control vs. Humalog (Lispro) in T1D: PRONTO-T1D Study

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

SAT660 Predictors Of Achieving Body Weight Reduction ≥20% With Tirzepatide In People With Overweight Or Obesity In SURMOUNT-1

Journal of the Endocrine Society, 2023-10, Vol.7 (Supplement_1)

2023

Volltextzugriff (PDF)

Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US

Current medical research and opinion, 2016-04, Vol.32 (4), p.669-680

2016

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(48)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(23)
Life Sciences & Biomedicine
(21)
Humans
(13)
Diabetes
(11)
Endocrinology & Metabolism
(9)
General & Internal Medicine
(9)
Type 2 Diabetes
(9)
Female
(8)
Medicine, General & Internal
(8)
Adult
(7)
Diabetes Mellitus, Type 2 - Drug Therapy
(7)
Insulin
(7)
Male
(7)
Insulin - Therapeutic Use
(6)
Basal Insulin
(5)
Hypoglycemic Agents - Therapeutic Use
(5)
Internal Medicine
(5)
Middle Aged
(5)
Weight Control
(5)
Cardiology
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Diabetes
(7)
Obesity
(6)
Canadian Journal Of Diabetes
(5)
Current Medical Research And Opinion
(4)
Diabetes Therapy
(4)
Endocrine Practice
(4)
Diabetes & Metabolism
(2)
Genetics
(2)
Oncology Letters
(2)
Bmj Open Diabetes Research & Care
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

Growth Hormone plus Childhood Low-Dose Estrogen in Turner's Syndrome

Identifying solutions to psychological insulin resistance: An international study

Growth Hormone Is Effective in Treatment of Short Stature Associated with Short Stature Homeobox-Containing Gene Deficiency: Two-Year Results of a Randomized, Controlled, Multicenter Trial

Key factors for overcoming psychological insulin resistance: an examination of patient perspectives through content analysis

Characterization of People Achieving Different Weight Reduction Categories with Tirzepatide

Predictors of Achieving Weight Reduction ≥30% with Tirzepatide in People with Obesity in SURMOUNT-1

Weight Reduction is Associated with Improved Quality of Life in Patients with Obesity: SURMOUNT-1

Characteristics and Efficacy of Tirzepatide in Participants with Young-Onset Obesity in SURMOUNT-1

Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis

Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26‐week PRONTO‐T1D study

1702836 Tirzepatide Improved Health-Related Quality of Life in Adults with Obesity or Overweight: Results from the SURMOUNT-3 phase 3 trial

1704957 Tirzepatide Improves Health-Related Quality of Life in Participants With Obesity or Overweight and Type 2 Diabetes: Results From Phase 3 SURMOUNT-2 Trial

1696673 Weight reduction over time in tirzepatide-treated participants by early weight loss response – post hoc analysis in SURMOUNT-1

Tolerability and Weight Reduction of Tirzepatide in Adults With Obesity or Overweight

Baseline Characteristics Associated with Time to Weight Plateau with Tirzepatide in SURMOUNT-1

1704946 Improvements in Physical Functioning Among Participants With Obesity With Limitations in Physical Function at Baseline: Results from SURMOUNT-1 and SURMOUNT-2 Trials

1089-P: Ultra Rapid Lispro (URLi) Improves Postprandial Glucose (PPG) Control and Time in Range (TIR) in T1D Compared with Humalog (Lispro): PRONTO-T1D Continuous Glucose Monitoring (CGM) Substudy

Phase 2, randomized, open‐label study of ramucirumab in combination with first‐line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non–small cell lung cancer

Correlates of basal insulin persistence among insulin-naïve people with type 2 diabetes: results from a multinational survey

1112-P: Ultra Rapid Lispro (URLi) Lowers Postprandial Glucose (PPG) and More Closely Matches Normal Physiological Glucose Response Compared with Other Rapid Insulin Analogs

1112-P: Ultra Rapid Lispro (URLi) Lowers Postprandial Glucose (PPG) and More Closely Matches Normal Physiological Glucose Response Compared with Other Rapid Insulin Analogs

144-OR: Ultra Rapid Lispro (URLi) Improves Postprandial Glucose (PPG) Control vs. Humalog (Lispro) in T1D: PRONTO-T1D Study

SAT660 Predictors Of Achieving Body Weight Reduction ≥20% With Tirzepatide In People With Overweight Or Obesity In SURMOUNT-1

Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US

Suchergebnisse filtern